Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2025 16:15 ET | Source: Castle Biosciences, Inc.

Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups

Castle Biosciences will share new data on DecisionDx-SCC and DecisionDx-Melanoma at the NCCN 2025 Annual Conference.
December 11, 2023 08:30 ET | Source: Coherus BioSciences, Inc.

Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI™ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx

– NCCN Guidelines recommend LOQTORZI as the only Preferred Category 1 treatment option in first-line treatment for adults with metastatic or recurrent locally advanced NPC in combination with...
September 07, 2017 08:10 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed Glioblastoma

TUSTIN, Calif., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
March 13, 2017 16:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments

-- Avid Revenue Guidance Increased to $60 - $65 Million for Full FY 2017 and Contracted Backlog of Future Business Currently at $70 Million ---- Multiple Preclinical Studies Demonstrating...
December 12, 2016 16:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments

-- Avid Posts Record Revenue of $23.4 Million During Second Quarter FY 2017 with Contracted Backlog of Future Business Currently at $73 Million -- -- Beta-2 Glycoprotein-1 (β2GP1) Identified as a...
September 06, 2016 08:45 ET | Source: Peregrine Pharmaceuticals Inc.

National Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple Cancers

TUSTIN, Calif., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing...
January 11, 2016 08:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers

-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 -- -- Phase II/III Study in HER2-Negative Metastatic...
January 06, 2016 08:05 ET | Source: Peregrine Pharmaceuticals Inc.

Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab

TUSTIN, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
March 21, 2013 15:09 ET | Source: National Comprehensive Cancer Network

NCCN Holds Second Annual State Oncology Society Forum

FORT WASHINGTON, Pa., March 21, 2013 (GLOBE NEWSWIRE) -- The National Comprehensive Cancer Network® (NCCN®) held its second annual State Oncology Society Forum during the NCCN 18th Annual...
March 21, 2013 10:30 ET | Source: National Comprehensive Cancer Network

NCCN Roundtable Considers the Changing Oncology Landscape: Evolution or Revolution?

FORT WASHINGTON, Pa., March 21, 2013 (GLOBE NEWSWIRE) -- The National Comprehensive Cancer Network® (NCCN®) hosted its second roundtable of the NCCN 18th Annual Conference: Advancing the...

Next Page keyboard_arrow_right